| Stewart, David J |
| Terminated | N/A | 6 | US | The Tack Endovascular System | Spectranetics Corporation | PAD - Peripheral Arterial Disease, PAD, Dissection, Arterial Dissection, Peripheral Arterial Disease, Peripheral Vascular Diseases | 06/24 | 06/24 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
| Recruiting | N/A | 125 | US | Cleaner Pro Thrombectomy System, Cleaner Vac Thrombectomy System | Argon Medical Devices, NAMSA | Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism | 06/26 | 09/26 | | |
| Recruiting | N/A | 300 | Europe, US | ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. | Inari Medical | Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome | 06/25 | 10/25 | | |
| Gordon, Michael S |
| Recruiting | 4 | 100 | Europe, Japan, US, RoW | dabrafenib, trametinib | Novartis Pharmaceuticals | Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | 12/27 | 12/27 | | |
| Terminated | 1/2 | 20 | US | SQZ-eAPC-HPV, Pembrolizumab | SQZ Biotechnologies | Adult Solid Tumor | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 172 | US | OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere | OncoResponse, Inc., OncoResponse, Inc. | Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma | 04/24 | 08/24 | | |
| Active, not recruiting | 1/2 | 128 | US | Oral NKT2152 | NiKang Therapeutics, Inc. | CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell | 05/25 | 09/26 | | |
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 5 | US | DCBY02 | DynamiCure Biotechnology | Advanced or Metastatic Solid Tumors | 02/24 | 02/24 | | |
| Active, not recruiting | 1 | 499 | Europe, US | Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1 | Agenus Inc. | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 01/25 | 12/27 | | |
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 64 | US | RBS2418, Pembrolizumab | Riboscience, LLC., Oncobay Clinical, Inc | Advanced Cancer | 09/25 | 10/25 | | |
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 66 | US, RoW | INV-9956 | Shenzhen Ionova Life Sciences Co., Ltd. | Advanced Metastatic Castration Resistant Prostate Cancer | 04/26 | 03/27 | | |
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 257 | US, RoW | DCSZ11, Pembrolizumab | DynamiCure Biotechnology | Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 740 | Europe, Canada, US, RoW | Dostarlimab | Tesaro, Inc. | Neoplasms | 05/26 | 10/27 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Martinez, Fernando |
PILLAR, NCT04636814 / 2020-003648-97: A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. |
|
|
| Recruiting | 3 | 3980 | Europe, US, RoW | CHF6001 1600µg, CHF6001 3200µg, Placebo, Roflumilast | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 09/27 | 09/27 | | |
| Recruiting | N/A | 60 | Europe | Shoulder Arthroplasy with PRIMA humeral stem | Limacorporate S.p.a, Iqvia Pty Ltd | Arthroplasty, Replacement, Shoulder | 12/26 | 12/26 | | |
| Shah, Manish A |
NCT03921021: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma |
|
|
| Completed | 2 | 17 | US | Telomelysin, OBP-301 | Weill Medical College of Cornell University, Oncolys BioPharma Inc | Esophagogastric Adenocarcinoma | 06/23 | 07/23 | | |
NCT02998268: Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 42 | US | Pembrolizumab, Keytruda, Taxol, Paclitaxel, Carboplatin | Weill Medical College of Cornell University, Merck Sharp & Dohme LLC | Esophageal Adenocarcinoma | 02/21 | 09/26 | | |
CA209-76L, NCT04021108: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol ) |
|
|
| Active, not recruiting | 2 | 80 | US | Nivolumab 240 MG | Weill Medical College of Cornell University, Bristol-Myers Squibb | Gastroesophageal Adenocarcinoma | 04/25 | 04/26 | | |
NCT06300463: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases |
|
|
| Recruiting | 2 | 24 | US | Botensilimab, AGEN1181, Balstilimab, AGEN2034, AGEN1423, Radiation | Weill Medical College of Cornell University, Agenus Inc. | Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer | 09/25 | 03/27 | | |
NCT06340711: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma |
|
|
| Recruiting | 2 | 27 | US | OBP-301, Suratadenoturev, Pembrolizumab, Keytruda | Weill Medical College of Cornell University, Merck Sharp & Dohme LLC, Oncolys BioPharma Inc | Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 04/26 | 04/28 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
NCT05480384: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction |
|
|
| Recruiting | 2 | 25 | US | Nivolumab, OPDIVO, Trastuzumab deruxtecan, ENHERTU | Brown University, AstraZeneca | Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer | 01/25 | 01/27 | | |
| Active, not recruiting | 1/2 | 115 | Europe, Canada, US | GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab | Nouscom SRL, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 04/25 | 11/26 | | |
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer |
|
|
| Active, not recruiting | 1 | 96 | Europe, US | ATP128, BI 754091, Ezabenlimab, VSV-GP128 | Amal Therapeutics, Boehringer Ingelheim | Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer | 05/25 | 08/25 | | |
| Recruiting | N/A | 240 | US | | Omron Healthcare Co., Ltd., University of Wisconsin, Madison, Children's Hospital Medical Center, Cincinnati, University of Chicago | Asthma in Children, Bronchitis, Bronchiolitis | 11/21 | 12/21 | | |
| Active, not recruiting | N/A | 949 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 07/24 | 08/25 | | |
| Recruiting | N/A | 2650 | Europe, Canada, Japan, US, RoW | Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 08/27 | 08/30 | | |
| Garland, Linda |
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study |
|
|
| Recruiting | 3 | 700 | US | Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806 | SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC | Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 03/25 | 03/28 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Stea, Baldassarre D |
RESTORE, NCT03862430: A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM |
|
|
| Recruiting | 2 | 87 | US | NanO2TM, Dodecafluoropentane emulsion (DDFPe), Placebo Saline Infusion, 0.9N NaCl | NuvOx LLC | Glioblastoma Multiforme | 06/25 | 09/25 | | |
| Gross, Robert |
GenTLE, NCT06063850: AMT-260 Gene Therapy Study in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy |
|
|
| Recruiting | 1/2 | 12 | US | AAV9-hSyn1-miGRIK2, AMT-260 | UniQure Biopharma B.V. | Mesial Temporal Lobe Epilepsy | 11/26 | 06/27 | | |
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate) |
|
|
| Completed | N/A | 167 | US | Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation | MedtronicNeuro | Temporal Lobe Epilepsy | 12/23 | 12/23 | | |
| Recruiting | N/A | 100 | US | Sham-stimulation, Active-stimulation | Abbott Medical Devices | Treatment Resistant Depression | 04/27 | 04/29 | | |
| Armstrong, David |
COVER DFUs, NCT05372809: Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs |
|
|
| Terminated | 3 | 42 | US | SkinTE, Autologous Heterogeneous Skin Construct, Control, Standard of Care | PolarityTE, Alira Health | Diabetic Foot | 02/24 | 02/24 | | |
NCT04267640: Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers |
|
|
| Recruiting | 2 | 60 | US | AMG0001, HGF plasmid, Collategene, beperminogene perplasmid, Placebo | AnGes USA, Inc. | Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot | 07/22 | 01/23 | | |
NCT03754465: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers |
|
|
| Active, not recruiting | 2 | 56 | US | ALLO-ASC-DFU, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells, Hydrogel SHEET(Vehicle control), Hydrogel sheet without Allogenic Mesenchymal Stem Cells | Anterogen Co., Ltd. | Diabetic Foot Ulcer | 11/23 | 05/24 | | |
NCT04497805: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers |
|
|
| Recruiting | 2 | 64 | US | ALLO-ASC-SHEET, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells | Anterogen Co., Ltd. | Diabetic Foot Ulcer | 12/24 | 06/25 | | |
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 200 | US | NuShield | Organogenesis | Diabetic Foot Ulcer | 11/21 | 12/21 | | |
BGWM, NCT06403605: Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 100 | US | Mirragen Wound Matrix, Fibracol | ETS Wound Care, LLC, Professional Education and Research Institute | Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot | 12/24 | 12/24 | | |
| Terminated | N/A | 8 | US | Pulsed splenic ultrasound, Active ultrasound, Ultrasound probe (no energy applied) | General Electric Research | Burn Wound, 2nd Degree Burn of the Skin | 12/24 | 12/24 | | |
NCT05797285: Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers |
|
|
| Completed | N/A | 26 | US | human keratin graft, ProgenaMatrix | ProgenaCare Global, LLC, Professional Education and Research Institute | Ulcer Healing, Diabetic Foot Ulcer | 12/23 | 12/23 | | |
NCT04564443: A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot |
|
|
| Active, not recruiting | N/A | 222 | US | Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Pressure Relief, Fibracol Wound Dressing, Calcium Alginate | Medaxis, LLC, Professional Education and Research Institute | Diabetic Foot Ulcer, Diabetic Foot | 12/24 | 12/24 | | |
NCT06035523: Clinical Study Evaluating Wound Closure With Endoform™ and Symphony™ |
|
|
| Recruiting | N/A | 50 | US | Endoform™ Antibacterial, Endoform™ Natural, Symphony™ | Aroa Biosurgery Limited, Professional Education and Research Institute | Wound Healing, Diabetic Foot, Chronic Foot Ulcer, Foot Ulcer | 06/24 | 06/24 | | |
NCT06681428: Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 240 | US | Allograft | Tides Medical, Professional Education and Research Institute | Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers | 11/26 | 11/26 | | |
NCT06035536: Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 120 | US | Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol | Aroa Biosurgery Limited, Professional Education and Research Institute | Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer | 12/24 | 12/24 | | |
| Recruiting | N/A | 1000 | Canada | | University Health Network, Toronto, Canadian Nutrition Society, Baxter Healthcare Corporation, Ontario Medical Supply | Parenteral Nutrition, Home | 12/29 | 12/29 | | |
| Miller, Elizabeth |
NCT04501939: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax |
|
|
| Active, not recruiting | 2 | 5 | US | Cirmtuzumab, Zilovertamab, Venetoclax, VENCLEXTA | University of California, San Diego, Oncternal Therapeutics, Inc | Chronic Lymphocytic Leukemia | 07/25 | 07/25 | | |
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer |
|
|
| Terminated | 1 | 122 | Europe, Canada, US, RoW | Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317 | Novartis Pharmaceuticals | BRAF V600 Colorectal Cancer | 09/24 | 09/24 | | |
| Sweitzer, Nancy K |
| Recruiting | 2 | 282 | Canada, US, RoW | JK07, Placebo | Salubris Biotherapeutics Inc | Heart Failure with Reduced Ejection Fraction, Heart Failure with Preserved Ejection Fraction | 12/25 | 06/26 | | |
NCT05322616: Single-Ascending Dose Study of JK07 in Subjects With HFpEF |
|
|
| Withdrawn | 1 | 56 | US | JK07, Matching Placebo | Salubris Biotherapeutics Inc | Heart Failure With Preserved Ejection Fraction | 05/23 | 05/23 | | |
| Bauman, Julie |
| Terminated | 2 | 16 | US | Ruxolitinib, Jakafi | University of California, San Francisco, Incyte Corporation | Head and Neck Squamous Cell Carcinoma | 10/23 | 10/23 | | |
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 1 | 85 | US | CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab | Cue Biopharma, Merck Sharp & Dohme LLC | Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma | 11/24 | 05/25 | | |
| Ryan, Elizabeth |
NCT06016088: A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection |
|
|
| Recruiting | 1/2 | 72 | US, RoW | RSP-1502, Tobramycin inhalation solution | Respirion Pharmaceuticals Pty Ltd | Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa | 12/25 | 12/25 | | |
| Chambers, Setsuko K |
| Terminated | 3 | 20 | Canada, US, RoW | Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo | Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 09/23 | 09/23 | | |
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076) |
|
|
| Recruiting | 3 | 186 | US | olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Genelux Corporation, GOG Foundation | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 08/25 | 10/26 | | |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer |
|
|
| Active, not recruiting | 2 | 125 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin | AbbVie | High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 05/26 | 05/26 | | |
|
| Jackson, Daniel L |
PANDA, NCT05347771: Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents |
|
|
| Recruiting | 2 | 240 | US | Dupilumab, Dupixent, IL4Ra mAb, Placebo, Placebo for Dupilumab | National Institute of Allergy and Infectious Diseases (NIAID), Childhood Asthma in Urban Settings (CAUSE), Regeneron Pharmaceuticals, Rho Federal Systems Division, Inc. | Asthma | 08/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 264 | US, RoW | STMC-103H, Placebo | Siolta Therapeutics, Inc. | Atopic Dermatitis, Type 1 Hypersensitivity | 11/24 | 10/25 | | |
| Larson, Paul |
| Recruiting | 1/2 | 37 | US | intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery | UniQure Biopharma B.V. | Huntington's Disease | 04/29 | 06/29 | | |
|
|
|
| Gonzalez, Victor |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
VOYAGE, NCT04708145: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial |
|
|
| Active, not recruiting | 4 | 150 | US | Aflibercept Injection, Eylea | Greater Houston Retina Research, Regeneron Pharmaceuticals, Clinical Trials Resource Group, LLC | Diabetic Retinopathy | 09/24 | 09/24 | | |
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis |
|
|
| Active, not recruiting | 4 | 125 | US | Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg | Alimera Sciences, CBCC Global Research | Uveitis, Posterior | 11/25 | 11/25 | | |
NCT06229665: Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) |
|
|
| Active, not recruiting | 2/3 | 75 | US | Valeda Light Delivery System | LumiThera, Inc., National Eye Institute (NEI) | Dry Age-related Macular Degeneration | 05/25 | 06/25 | | |
NCT05532735: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion |
|
|
| Completed | 2 | 16 | US | ANXV | Annexin Pharmaceuticals AB, InFocus Clinical Research | Retinal Vein Occlusion | 07/24 | 11/24 | | |
NCT05573100: The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) |
|
|
| Completed | 2 | 67 | US | CU06-1004, SAC-1004, CU06, CU06-RE | Curacle Co., Ltd., Théa Open Innovation, France | Diabetic Macular Edema | 05/23 | 06/23 | | |
LEOPARD, NCT05608837: Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects with Uveitis Related and Post Surgical Macular Edema |
|
|
| Recruiting | 2 | 24 | US | OCS-01, dexamethasone ophthalmic suspension eye drops | Quan Dong Nguyen, Global Ophthalmic Research Center (GORC), Oculis | Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative | 07/25 | 09/25 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Drake, Kendra |
NCT04942496: A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations |
|
|
| Not yet recruiting | 4 | 44 | US | Chlorhexidine Gluconate, Hibi Universal Bathing System, 0.1% SLS, Distilled Water | Molnlycke Health Care AB, BioScience Laboratories, Inc. | Skin Irritancy Potential | 06/21 | 07/21 | | |
| Borad, Mitesh J |
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers |
|
|
| Active, not recruiting | 2/3 | 150 | US | CTX-009, Paclitaxel | Compass Therapeutics | Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer | 07/25 | 12/25 | | |
NCT05223816: An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 97 | US | VG161, Nivolumab Injection [Opdivo] | Virogin Biotech Canada Ltd | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 10/25 | 12/25 | | |
| Recruiting | 1/2 | 242 | US | DF9001, pembrolizumab, KEYTRUDA® | Dragonfly Therapeutics, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 08/25 | 11/27 | | |
NCT04717375: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 456 | Europe, Canada, US, RoW | SAR444881, BND-22, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed | Sanofi | Cancer, Neoplasm | 02/27 | 02/27 | | |
| Recruiting | 1 | 410 | Europe, Canada, US | PF-08046050, SAR445953; SGN-CEACAM5C | Seagen Inc., Sanofi | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 03/29 | 03/30 | | |
NCT05115292: A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma |
|
|
| Active, not recruiting | 1 | 85 | US | BJ-005 | BJ Bioscience, Inc. | Advanced Solid Tumor or Lymphoma | 10/24 | 10/25 | | |
| Recruiting | 1 | 120 | Japan, US, RoW | EO-3021 | Elevation Oncology | Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms | 09/28 | 12/28 | | |
| Lane, Richard D |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Daines, Cori |
NCT06016088: A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection |
|
|
| Recruiting | 1/2 | 72 | US, RoW | RSP-1502, Tobramycin inhalation solution | Respirion Pharmaceuticals Pty Ltd | Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa | 12/25 | 12/25 | | |
| Sperling, Michael |
NCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy |
|
|
| Recruiting | 4 | 90 | US | Cenobamate | SK Life Science, Inc. | Focal Onset Seizure | 05/27 | 07/27 | | |
| Completed | 3 | 270 | Europe, Canada, Japan, US, RoW | Placebo, Soticlestat, TAK-935 | Takeda | Lennox Gastaut Syndrome (LGS) | 01/24 | 01/24 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | Soticlestat, TAK-935 | Takeda | Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS) | 05/26 | 05/26 | | |
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures |
|
|
| Completed | 2 | 154 | Europe, US, RoW | CVL-865, Placebo | Cerevel Therapeutics, LLC | Seizures | 05/24 | 05/24 | | |
NCT05473442: Study of EQU-001 for Uncontrolled Focal Onset Seizures |
|
|
| Terminated | 2 | 27 | US, RoW | EQU-001, Matching Placebo | Equilibre Biopharmaceuticals B.V. | Focal Onset Seizures | 07/23 | 07/23 | | |
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
|
|
| Recruiting | 1/2 | 40 | US | NRTX-1001, GABA-secreting interneurons, Sham Comparator | Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM) | Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis | 05/25 | 05/26 | | |
NCT05738226: EpiCare@Home Validation Study for Focal Onset Seizures |
|
|
| Recruiting | N/A | 80 | US | EpiCare@Home, wearable multimodal seizure monitoring system | Byteflies, Thomas Jefferson University | Epilepsy, Seizures, Seizures, Focal, Seizure, Refractory | 06/23 | 12/23 | | |
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate) |
|
|
| Completed | N/A | 167 | US | Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation | MedtronicNeuro | Temporal Lobe Epilepsy | 12/23 | 12/23 | | |
| Shaheen, Montaser |
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) |
|
|
| Recruiting | 2 | 267 | US, RoW | mRNA-4157, Pembrolizumab | ModernaTX, Inc., Merck Sharp & Dohme LLC | Melanoma | 09/29 | 09/29 | | |
|
|
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 230 | US, RoW | Phase 1b: APG-115+pembrolizumab, KEYTRUDA® | Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 12/24 | 03/25 | | |
NCT06035744: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 86 | US | CLN-617, Pembrolizumab, Keytruda | Cullinan Therapeutics Inc. | Advanced Solid Tumor | 06/28 | 06/28 | | |
| Chalasani, Pavani |
| Active, not recruiting | 2/3 | 849 | Europe, US, RoW | eftilagimod alpha, IMP321, efti, LAG-3Ig, eftilagimod alfa, Paclitaxel, placebo, placebo matching eftilagimod alpha | Immutep S.A.S., Immutep S.A.S. | Breast Carcinoma | 10/26 | 07/27 | | |
| Recruiting | 2 | 30 | US | Tucatinib, TUKYSA, Eribulin, HALAVEN, Trastuzumab, HERCEPTIN | Criterium, Inc. | Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | 06/27 | 08/27 | | |
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 70 | US | Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care | Criterium, Inc. | Breast Cancer | 12/27 | 12/27 | | |
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
|
|
| Recruiting | 2 | 44 | US | Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy | SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8 | 12/27 | 12/28 | | |
| Active, not recruiting | 1/2 | 300 | US, RoW | CAB-AXL-ADC, PD-1 inhibitor | BioAtla, Inc. | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 01/25 | 01/25 | | |
| Completed | 1/2 | 132 | Europe, US, RoW | CAB-ROR2-ADC, BA3021, PD-1 inhibitor | BioAtla, Inc., BioAtla Inc. | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 12/24 | 12/24 | | |
| Recruiting | N/A | 422 | US | | Personalis Inc. | TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | 08/25 | 12/25 | | |
